Health
For founders pursuing commercial opportunities predicated on translational science and technology innovations that improve human health and wellness.
- All Ventures
ImmuneAdvice GmbH
ImmuneAdvice GmbH is a pre-seed, preclinical radiopharmaceutical start-up based in Reutlingen, Germany, developing next-generation immune cell tracers (ICE-Ts) for PET imaging. Our lead candidate, CD4 ICE-T, non-invasively identifies the immune status of tumors – distinguishing “hot” from “cold” microenvironments – and enables early detection of resistance to immune checkpoint inhibitors (ICIs). By providing actionable insights into a patient’s response to immunotherapy, our ICE-Ts open the door to timely, personalized treatment adjustments, especially for melanoma and NSCLC patients – redefining cancer care.
Ovo Labs
Ovo Labs is developing therapeutics to improve egg quality and increase IVF success rates, particularly for women in their mid-30s to early 40s. Currently, no treatments exist to enhance egg quality, which declines significantly with age—resulting in only a 13% chance of conception by age 40. Ovo Labs builds on 20 years of pioneering research in the field of female infertility in the laboratory of Prof. Melina Schuh and holds an exclusive global license covering an entire portfolio of therapeutic candidates targeting egg quality. The company raised its Seed Round in 2025 in order to take its Lead Therapeutic, EmbryoProtect1, towards clinical studies in humans
NeutroGen Therapeutics
NeutroGen Therapeutics (NTX) is developing a novel allogeneic neutrophil cell therapy for neutropenia—a condition prevalent in leukemia patients and individuals undergoing chemotherapy, associated with high infection risk and mortality. NTX’s patent-pending therapy uses a stem cell-based protocol that enables the production of storable, genetically modifiable neutrophils, providing a faster, more reliable treatment. The platform also holds promise for expansion into cancer, autoimmunity, and multi-drug resistance indications.
Kyron.bio
Kyron.bio is pioneering a new frontier in drug design by engineering therapeutic production cells to precisely control the sugars that coat protein surfaces. These sugar molecules dramatically influence therapeutic function and performance. Kyron.bio’s technology has demonstrated the ability to prevent unwanted immune responses to antibody therapies and enhances the stability and efficacy of protein-based drugs used in treating cancer, autoimmune diseases, and other conditions, addressing critical unmet clinical needs.
aitiologic
Aitiologic is a precision diagnostics company pioneering the next generation of liquid biopsy. Its patented aitios®platform integrates artificial intelligence with multi-modal DNA profiling to decode previously inaccessible molecular signals from blood – enabling early, non-invasive detection of treatable diseases. Beginning with prenatal care, Aitiologic is developing an AI-powered blood test to detect hundreds of treatable fetal conditions – before symptoms arise and ahead of conventional diagnostics – giving every child the best possible start to a healthy life. With broader applications spanning maternal health and oncology, Aitiologic is redefining how and when we detect disease – transforming early insight into timely intervention and better outcomes at every stage of life.
“TEAM: (i) Andreas is a great founder: he started and exited a company before (which is rare in life sciences, as development cycles from cradle to exit are usually very long and risk of failure is exceptionally high) and is very coachable (I worked with him on the company’s latest pitch deck and found the discussions always very productive. His responsiveness is truly remarkable when it comes to iterations of documents and presentations). (ii) The people Andreas recruited also made a very good impression on me (I visited the company in Vienna and got to know other members of the team). While some might not be natural pitch machines, they all seem to have a very deep understanding of what they are doing and appear to be true domain experts. This once again proves the saying that A people hire A people (and B people hire C people) right…. (iii) Rebecca, the Chief Medical Officer (who I haven’t met in person yet), has vast experience in the field and appears to be a true enrichment for the team. (iv) Globally leading experts from medicine and industry have expressed strong interest in supporting the company long-term, a potential game changer for the business, offering genuine access to key scientific and industry networks.
BUSINESS: (i) I do believe (and whether this is true or not yet needs to be proven by the company. But this challenge is inherent to any groundbreaking technological development) that the company has the potential to revolutionize liquid biopsy in two fields: oncology and non-invasive pre-natal tests (NIPT). (ii) While it goes without saying that a step-change in liquid biopsy in the field of oncology would hold tremendous commercial potential, an advanced NIPT product alone would justify the foundation of a business around this challenge. (iii) While current tests are limited in scope (the Harmony Test being the most commonly known here), aitiologic’s product would offer a much broader array of results at a very compelling price tag. (iv) As the company is still in its early days, the true value of the envisaged NIPT product in terms of expectable reimbursement can only be a rough estimate at this stage. Nevertheless, the ability to test pregnant women for potentially hundreds of (treatable) diseases without the risk of puncture, leaves plenty of room for optimism. (v) The oncology-related test would be developed at a later stage as the team is currently fully focused on its first program. Nevertheless, the technology (see below) holds the potential to also bring substantial value to this field, an application which could, commercially speaking, be multiple orders of magnitude larger in size than NIPT.
TECHNOLOGY: (i) Last but not least, I really like the idea of identifying cell-free DNA (cfDNA) through liquid biopsy (versus puncture, which comes with considerable risk and cost). (ii) Being a typical case of technological convergence, the company leverages the potential of AI and applies it to the interpretation of scientific results derived from blood tests, using aitiologic’s patented technology. In my perception, all groundbreaking businesses in life sciences will have to develop the ability to master the combination of computational engineering and natural sciences. Aitiologic has without a doubt the potential to be leading in this craft.”
– Constantin Schwaab, CEO, Wirelane GmbH
Captain T Cell GmbH
Captain T Cell is advancing next-generation TCR-T cell therapies to overcome the limitations of immunotherapy in solid tumors. Its proprietary genetic “toolbox” enables T cells to achieve complete responses in preclinical models at a fraction of the dose used by competitors, unlocking automated, scalable manufacturing at significantly lower cost. With a best-in-class autologous program quickly approaching the clinic and a first-in-class allogeneic “off-the-shelf” platform showing complete responses in preclinical models, Captain T Cell is well-positioned to deliver impactful therapies. Backed by a combination of private investment and significant non-dilutive funding, the company offers a potentially game-changing approach in a rapidly growing market.
SoundCell
SoundCell developed the MelodyOne: a rapid nanotechnology Antimicrobial Susceptibility Testing (AST) platform that detects bacterial resistance within just 1 hour, far faster than traditional methods. Using graphene-based sensors, it measures microscopic bacterial vibrations to determine if antibiotics are working in real time. With quicker AST results, physicians can promptly switch from broad-spectrum to narrow-spectrum antibiotics, promoting more prudent antibiotic use and allowing patients to receive effective treatments sooner. The cornerstone of their technology lies in leveraging bacterial nanomotion to assess antibiotic susceptibility. This approach bypasses the need for bacterial growth rates, which is the limiting factor in current systems that require up to two days to provide results.